Oramed Pharmaceuticals Inc. (ORMP) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on oral delivery of therapeutic proteins, primarily oral insulin. The company is currently evaluating strategic opportunities and has significantly diversified its asset base through financial investments in Scilex Holding Company, Alpha Tau Medical Ltd., and real estate projects, alongside its core R&D activities.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | Q3 2024 (3 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $2,000 | $0 | $0 |
| Net Income (Loss) | $48,389 | $54,007 | $(19,642) | $(8,904) |
| Operating Loss | $(2,427) | $(9,416) | $(3,089) | $(9,186) |
| Financial Income (Loss), Net | $61,470 | $74,278 | $(15,420) | $3,902 |
| Cash and Equivalents | $52,179 | $52,179 | $42,104 | $9,055 |
| Total Assets | $220,493 | $220,493 | $155,278 | $155,278 |
| Working Capital | $129,998 | $129,998 | $137,536 | $137,536 |
Note: All figures in thousands of U.S. Dollars unless otherwise noted.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $48.4 million for Q3 2025, a significant turnaround from a net loss of $19.6 million in Q3 2024. This is driven almost entirely by non-operating financial income.
- Financial Income Surge: Financial income increased to $61.5 million in Q3 2025 from a loss of $15.4 million in the prior year quarter. This is primarily due to the revaluation of investments in Alpha Tau Medical Ltd. ($22.3 million gain) and Scilex Holding Company ($34.2 million gain).
- Revenue Recognition: The company recognized $2.0 million in revenue during the nine months ended September 30, 2025, related to the HTIT License Agreement following a waiver of claims. No revenue was recognized in the comparable 2024 period.
- Investment Portfolio: Total assets increased by approximately 42% year-over-year, largely due to the acquisition of a ~17% stake in Alpha Tau and increased fair value of Scilex-related assets (Tranche A/B Notes and warrants).
- Operating Expenses: R&D expenses decreased 49% in Q3 2025 compared to Q3 2024, while G&A expenses increased 50%, primarily due to stock-based compensation.
Guidance, Outlook, and Risks
- Clinical Strategy: Management plans to initiate a smaller, 60-patient US-based clinical trial for oral insulin targeting high-responder subgroups identified in previous Phase 2/3 data. This aims to validate efficacy cost-effectively.
- Scilex Transactions: The company holds significant exposure to Scilex via Tranche A and B Notes and warrants. An Option Agreement allows Scilex to repurchase remaining "Subsequent Penny Warrants" for up to $27 million. The first tranche ($13 million) was completed in September 2025. Full completion is contingent on Scilex's liquidity.
- Strategic Investments: The company has diversified into real estate (Hapisga Project, Tama 38 Project) and equity investments (Alpha Tau, BioXcel via RoyaltyVest). Management views these as enhancing financial flexibility but notes they carry significant risk.
- Liquidity: With approximately $52.2 million in cash and equivalents and a working capital surplus of $130 million, management believes it can fund operations for at least the next 12 months. However, future R&D expansion will require additional capital.
- Risks: Key risks include the failure of Alpha Tau to achieve clinical success, Scilex's inability to repay notes or repurchase warrants, and the volatility of real estate investments. The company also faces geopolitical risks due to operations in Israel.
Investor Verification Checklist
- Scilex Liquidity: Verify Scilex's ability to fund the remaining $14 million warrant repurchase and service its debt obligations, as this impacts Oramed's asset valuation.
- Alpha Tau Valuation: Assess the sustainability of the Alpha Tau stock price appreciation driving the $27 million unrealized gain; this is a non-cash item subject to market volatility.
- Clinical Trial Scope: Confirm the design and regulatory acceptance of the proposed 60-patient oral insulin trial, as it represents a pivot from previous larger Phase 3 attempts.
- Real Estate Exposure: Review the collateral coverage and exit strategies for the Hapisga and Tama 38 real estate loans, which are measured at fair value.
- Stock Buyback: Monitor the execution of the $20 million stock repurchase program, which has reduced share count but impacts cash reserves.